Currently Approved Poly (Adenosine Diphosphate-Ribose) Inhibitors in Ovarian Cancer: Current Status and Future Directions

DOI: 10.2174/2212697X05666180706161252 Abstract: Background: Poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors have entered into the clinic rapidly and are becoming a powerful therapeutic tool, especially in the management of BRCA associated ovarian cancers. PARP inhibitors have exploited the homologous recombination deficiency, present in up to 50% of ovarian cancers, through synthetic lethality: A novel therapeutic approach to this disease. Objective: Through an extensive review of PARP inhibitors we evaluated the existing evidence in the clinical trial as monotherapy and combined with chemotherapy in ovarian cancer.